Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
Xiaomi Shares Jump on Europe EV Expansion Plan 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
Milei Threatens Falkland Oil Firms With Sanctions 
South Korea, US Discuss Chip Investments Amid Tariff Plans 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
Add as a preferred source on Google
ALPHARETTA, Ga., March 08, 2018 -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, announced today that its Chief Executive Officer and President, Daniel H. White, will present at the Cowen and Company 38th Annual Health Care Conference on Monday, March 12, 2018 at 4:10 p.m. ET at the Boston Marriott Copley Place in Boston, MA.
A live webcast of the presentation can be accessed on the company’s website at www.clearsidebio.com under the “Events & Presentations” tab in the “Investor Relations” section. Following the conference, the presentation webcast will be archived on the website for approximately 30 days.
About Clearside
Clearside Biomedical, Inc., headquartered in Alpharetta, GA, is a late-stage clinical ophthalmic biopharmaceutical company that envisions a world without blindness. Clearside relentlessly pursues transformative, elegant, precise solutions to restore and preserve vision. Clearside is developing advanced clinical and preclinical product candidates using a proprietary treatment approach offering unprecedented access to the back of the eye through the suprachoroidal space (SCS™). This offers potentially meaningful treatment benefit to patients suffering from sight-threatening diseases like uveitis, retinal vein occlusion, diabetic macular edema and wet age-related macular degeneration.
Contacts:
Stephen Kilmer
Investor Relations
(678) 270-3631
[email protected]
Charles Deignan
Chief Financial Officer
(678) 270-4005
[email protected]
